This tau aggregation into NFTs eventually leads to neuronal death and there are currently no known treatments to slow or prevent the progression of the disease. My doctoral work in Dr. Gamblin’s lab focuses on identifying compounds screened from Aspergillus nidulans secondary metabolites that can inhibit the aggregation of tau and disassemble already formed tau aggregates. Further examination of compounds with inhibition and disassembly activity will be done to determine their interactions by characterizing the binding affinity and binding sites with the tau protein. Another aspect of my research will be to explore the compound structures and to modulate the functional groups or side chains to see if this improves the inhibition or disassembly activities of the compounds.
Entered program in the fall of 2014.
Mentor: T. Chris Gamblin, Ph.D., Vanderbilt University
Mentor’s Academic Department: Molecular Biosciences, KU-L
2016 Chemistry-Biology Interface Career Development Conference, University of Michigan
2016 10th Annual Drug Discovery for Neurodegeneration Conference, Miami Beach, FL
2015 NIH Chemical Biology Training Grant Symposium, University of Kansas
Selected Awards & Honors
2016 Alzheimer’s Drug Discovery Foundation Young Investigator Scholarship Award
2015-2017 NIH Dynamic Aspects of Chemical Biology Fellowship